Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
12:45pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Editas (EDIT) delivered earnings and revenue surprises of 21.79% and 181.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine GAAP EPS of -$0.61 beats by $0.13, revenue of $12.47M
11:35am, Thursday, 24'th Feb 2022 Seeking Alpha
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
11:30am, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q4 2021 Results - Earnings Call Transcript
11:25am, Thursday, 24'th Feb 2022
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q4 2021 Results - Earnings Call Transcript
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
09:15am, Thursday, 24'th Feb 2022
Editas (EDIT) delivered earnings and revenue surprises of 21.79% and 181.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine Q4 2021 Earnings Preview (NASDAQ:EDIT)
05:31pm, Wednesday, 23'rd Feb 2022 Seeking Alpha
Editas Medicine (NASDAQ:EDIT) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.73 and the consensus…
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
04:44pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
01:06pm, Wednesday, 23'rd Feb 2022
Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
01:06pm, Sunday, 20'th Feb 2022 Benzinga
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
On the regulatory front, the Food and Drug A
Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates
10:45pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Prothena (PRTA) delivered earnings and revenue surprises of 4.05% and 324.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Editas Medicine (EDIT) Report Negative Earnings Next Week? What You Should Know
08:03pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update
11:15am, Wednesday, 16'th Feb 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thurs
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update
11:15am, Wednesday, 16'th Feb 2022 Benzinga
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT ), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results for the fourth quarter and full year 2021. To access the conference call: U.S. callers should dial … Full story available on Benzinga.com
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update
06:15am, Wednesday, 16'th Feb 2022
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursda
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
05:21pm, Monday, 14'th Feb 2022 Zacks Investment Research
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
